Skip to content
DataLookout
Menu

CTL-DP 01NCT04180059

Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation

StatusRecruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 10 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Primary completion date changed from estimate of Jul 2027 to Jul 8, 2026
    • Study completion moved earlier from Aug 2027 to Dec 2026
    • Study description expanded, about 2 words
  2. Notable Primary completion date: Apr 2025 to Jul 2027
    • Study completion date: Apr 2026 to Aug 2027
    v10
  3. Minor Primary completion date: Feb 2025 to Apr 2025
    • Study completion date: Feb 2027 to Apr 2026
    v9
  4. Notable Enrollment target: 20 to 6
    • Study completion date: Sep 2025 to Feb 2027
    • Study description expanded, about 145 words
    v8
  5. Notable Primary endpoint revised
    • Secondary endpoints: details revised at 1 of 8 entries
    v7
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Eligibility criteria expanded, about 2 wordsv6
  2. Notable Primary completion date: Sep 2022 to Feb 2025
    • Enrollment target: 24 to 20
    • Study completion date: Mar 2023 to Sep 2025
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2020 to Feb 9, 2020
    • Site details revised
    v3
  4. Minor Study description shortened, about 2 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

determine maximal tolerated dose of infusion of a third party suicide gene-transduced anti-HLA-DPB1*04:01 CD4+ T cell clone in HLA-DPB1*04:01 tumor positive recipients receiving an allo-HSCT from a HLA-DPB1*04:01 negative alternative donor.
Timeframe: 4 weeks after CTL injection

Secondary (8)

survival and persistence of the clone injected
immune reconstitution
incidence of relapse
survival
GVHD incidence
Show 3 moreShow less
mortality
complete remission
side effects of Clone

Arms and interventions

CTL 19 : T cell therapyExperimental

Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg. After study of toxicity of the 4 injected patients, choice has been made to stop the CRM method to choose the dose and to test only 2 doses for each last patients : 100 x 10\^4 cells/kg (actual level 5) and 500 x 10\^4 cells/kg (choice based on compassionnal injections data at the level 5)

Combination products: CTL 19

Sites

1 site in 1 country

  • Chu de NantesNantes, France